S
ELVN icon

SignatureFD’s Enliven Therapeutics ELVN Stock Holding History

SignatureFD’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.1K Buy
336
+100
+42% +$4.25K ﹤0.01% 2421
2026
Q1 		$9.25K Buy
236
+210
+808% +$5.82K ﹤0.01% 2549
2025
Q4 		$400 Sell
26
-21
-45% -$418 ﹤0.01% 3254
2025
Q3 		$962 Buy
47
+21
+81% +$423 ﹤0.01% 3100
2025
Q2 		$522 Buy
+26
New +$492 ﹤0.01% 3099

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

SignatureFD's ELVN Position: Q2 2026 in Review

SignatureFD increased its Enliven Therapeutics (ELVN) stake by 42% in Q2 2026, buying an estimated $4.25K and bringing the position to 336 shares worth $17.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2421.

SignatureFD first reported a position in ELVN in Q2 2025 and has held it in 5 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • SignatureFD held 336 shares of Enliven Therapeutics worth $17.1K as of Q2 2026.
  • SignatureFD bought 100 Enliven Therapeutics shares in Q2 2026, an estimated $4.25K.
  • Enliven Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #2421 holding.
  • SignatureFD first reported a position in Enliven Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.